The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

Not Applicable

Active, not recruiting

Conditions: Coronary Disease
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Stenosis

Interventions: Device: Percutaneous Coronary Intervention

Registration Number: NCT04192747

Lead Sponsor: Elixir Medical Corporation

Brief Summary: The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

Detailed Description: The Bioadaptor RCT Study is a prospective, 1:1 randomized study of parallel designed, that will enroll up to 444 patients requiring treatment of up to two de novo coronary lesions of ≤ 34 mm in length in vessels of ≥ 2.25 mm and ≤ 4.0 mm in diameter.

One or two designated target lesions, located in separate epicardial vessels (RCA, LCX or LAD), and meeting the inclusion/exclusion criteria may be treated with the ELX1805J (DynamX Bioadaptor) or Resolute Onyx stent

The primary safety endpoint is Target Lesion Failure (TLF) at 12 months. TLF is a composite endpoint defined as cardiac death, target vessel MI, and clinically-indicated target lesion revascularization

Additional secondary safety and effectiveness endpoints will be evaluated at 30 days, 6 and 12 months and 2-5 years.

Using visual assessment, the target lesion must measure ≥ 2.25 mm and ≤ 4.0 mm in diameter and ≤ 34 mm in length able to be covered by a single ELX1805J or Resolute Onyx stent including 2 mm of healthy vessel on either side of the planned treatment area.

The patient will be eligible for device implantation only after satisfactory lesion pre-dilatation defined as: ≥ TIMI 2 flow, and no dissection greater than Grade B (NHLBI) able to be covered with a single device

Recruitment & Eligibility

Status: ACTIVE_NOT_RECRUITING

Sex: All

Target Recruitment: 445

Inclusion Criteria

General Inclusion Criteria

Patients who meet all of the following criteria are eligible:

Patient must be ≥ 20 years of age.
Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)
Patients who are able to take dual anti-platelet therapy for 1 year following the index procedure and anticoagulants prior to/during the index procedure.
The subject is an acceptable candidate for Percutaneous Transluminal Coronary Angioplasty (PTCA), stenting, and emergent Coronary Artery Bypass Graft (CABG) surgery.
The subject or subject's legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board or Ethics Committee of the respective clinical site.
Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing
Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing
Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure
Target lesion(s) must be de novo and located in a native coronary artery with a vessel mean diameter of ≥ 2.25 and ≤ 4.0 mm.
Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and < 100% with a TIMI flow of > 1. When two target lesions are treated, they must be located in separate major epicardial vessels
visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 14/15/18/23/28/32/38 mm ELX1805J stent and have at least 2 mm of healthy vessel on either side Or
The visually estimated target lesion length is ≤ 34mm mm and must be able to be covered by a single 15/18/22/30/34/38 mm ZES stent respectively and have at least 2 mm of healthy vessel on either side.
The lesion(s) must be successfully pre-dilated prior to enrollment Mandatory pre-dilatation includes the use of 2 orthogonal views to confirm lesion inclusion and exclusion criteria and successful pre-dilatation defined as balloon inflation without waist and a lumen diameter no less than 0.5 mm smaller than the vessel diameter.
Percutaneous intervention of lesions in a non-target vessel if:
- Not part of a another clinical investigation
- ≥ 30 days prior to the study index procedure
- ≥ 6 months after the study index procedure (planned)
Percutaneous intervention of lesions located in the target vessel if:
- Not part of a clinical investigation
- ≥ 6 months prior to the study index procedure
- >12 months after the study index procedure (planned)
- Previous intervention was distal to and >10 mm from the target lesion

Exclusion Criteria

The patient was diagnosed with an acute myocardial infarction within the past 72 hours and the CK and CKMB have not returned to normal (or cTn >15x ULN) and the patient is experiencing clinical symptoms indicative of ongoing ischemia
Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, cobalt, nickel, chromium, molybdenum, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated
Patients with a history of allergic reaction or serious hypersensitivity to drugs exhibiting interactions with sirolimus, zotarolimus, everolimus, tacrolimus, temsirolimus, biolimus and other rapamycin, derivatives or analogues) or similar drugs
Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors.
Patient presenting with chronic (permanent) atrial or ventricular arrhythmia or current unstable ventricular arrhythmias
Patient has a known left ventricular ejection fraction (LVEF) < 30%
Patient has received a heart or other organ transplant or is on a waiting list for any organ transplant
Patient has a malignancy that is not in remission.
Patient is receiving immunosuppression therapy other than steroids and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures.
Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected to have cirrhosis of Child-Pugh ≥ Class B within 7 days before study procedure
Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL within 7 days before study procedure, or patient on dialysis)
Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months
Patient has had a significant GI or urinary bleed within the past six months
Patient has severe symptomatic heart failure (i.e., NYHA class IV)
Patient has a medical condition that precludes safe 6 French sheath insertion
Patient has other medical illness or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)
Patient is already participating in another clinical research study which has not reached the primary endpoint (long-term follow-up is not an exclusion)
Other patients whom primary investigator or subinvestigator determined to be ineligible for this clinical study
Patients with bypass graft to the target vessel or lesion is located in a bypass graft
Patients with stent implanted within 10 mm of proximal or distal end of target lesion
Patients with a target lesion involving a bifurcation of which the side branch will be jailed by the struts and:
- Side branch ≥ 2.5 mm in diameter,
- Side branch requiring predilatation (including Kissing Balloon Technique), or
- Side branch has an ostial lesion or lesion with > 50% stenosis
Patients suspected or confirmed with the QCA analysis of having stenotic lesion of more than 50% in target vessel in addition to target lesion
Patients with target lesion in ostia located within 5 mm of origin of LAD, LCX or RCA
Patients with stenotic lesion in left main trunk
Patients with target lesion that is a chronic total occlusion (CTO) or ≤ TIMI 1 coronary flow in the target vessel
Patients with target vessel that contains thrombus as indicated in pre-procedure angiographic, IVUS or OCT images
Excessive tortuosity ≥ two 45° angles or extreme angulation (≥ 90°) proximal to or within the target lesion
Patients with target vessel that has moderate to severe calcification that prevents complete angioplasty balloon (POBA with non-compliant balloon, or scoring balloon,) inflation or requires other devices such as rotational atherectomy, rotoblator.
Patients with dissection of Grade A or B that cannot be covered (including 2mm distal to the dissection) with a single study device or with dissection of Grade C or higher
Patients with 2 or more target lesions on 1 branch or target lesions on 3 branches that need to be treated during study procedure
Target lesion involves a myocardial bridge

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Elixir Bioadaptor (ELX1805J)	Percutaneous Coronary Intervention	The Elixir Bioadaptor (ELX1805J) 2.25 - 4.0 mm diameter and 14,15,18, 23, 28, 32 and 38 mm in length
Medtronic Resolute Onyx Stent	Percutaneous Coronary Intervention	The Medtronic Resolute Onyx Stent 2.25 - 4.0 mm diameter and 15, 18, 22, 30, 34 and 38 mm in length

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Target Lesion Failure (TLF)	12 Months	The primary endpoint of the BIOADAPTOR RCT is Target Lesion Failure (TLF), which is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated TLR

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Target Lesion Failure (TLF)	Through 12 months post-procedure	TLF is a composite endpoint defined as cardiovascular death, target-vessel MI, and Clinically-Indicated TLR
Percentage of Participants With Patient Oriented Clinical Endpoint	Through 12 months	Overall cardiovascular outcomes from the patient's perspective. This endpoint is a composite endpoint that includes all-cause mortality (cardiac and non-cardiac), stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)
Percentage of Participants With Composite of All-cause Mortality	Through 12 months post-procedure	A composite of all-cause mortality, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)
Percentage of Participants With Composite of Cardiovascular Death, TVMI and ID-TVR Revascularization	Through 12 months	Composite of cardiac death, target vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR)
Percentage of Participants With Cardiovascular Death, Stroke, MI and Revascularization	Through 12 months	Composite of cardiovascular death, stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)
Percentage of Participants With Cardiovascular Death, MI and Revascularization	Through 12 months	Composite of cardiovascular death, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)
Percentage of Participants With Clinically Indicated Target Lesion Revascularization (CI-TLR)	Through 12 months post-procedure	Number of Patients with Clinically Indicated Target Lesion Revascularization (CI-TLR)
Percentage of Participants With Target Lesion Revascularization (TLR)	Through 12 months post-procedure	Target lesion revascularization
Percentage of Participants With Target Vessel Revascularization (TVR)	Through 12 months post-procedure	Re-PCI or CABG of the target vessel due to in-segment restenosis or other complications
Percentage of Participants With Clinically Indicated TVR (CI-TVR)	Through 12 months post-procedure	Re-PCI or CABG in the target vessel due to restenosis or other complications
Percentage of Participants With Revascularization (Target Vessel or Non-target Vessel)	Through 12 months post procedure	Revascularization of the target vessel or non-target vessel due to in-segment restenosis or other complications
Percentage of Participants With Q-wave MI	Through 12 months post-procedure	CK post procedure is twice the upper limit of the reference value or higher, with new pathological Q-wave on 2 or more contiguous ECG leads and if CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.
Percentage of Participants With Non Q-wave MI	Through 12 months post-procedure	CK post procedure is twice the upper limit of the reference value or higher, without new pathological Q-waves. If CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.
Percentage of Participants With MI (Target Vessel or Non-target Vessel)	Through 12 months post procedure	MI is defined as per the Academic Research Consortium (ARC-2) criteria
Percentage of Participants With Target Vessel MI	Through 12 months post procedure	MI is defined as per the Academic Research Consortium (ARC-2) criteria
Percentage of Participants With All-cause Mortality	Through 12 months post-procedure	As defined per the Academic Research Consortium (ARC-2) criteria
Percentage of Participants With Cardiovascular Death	Through 12 months post procedure	As defined as per the Academic Research Consortium (ARC-2) criteria
Percentage of Participants With Composite of Cardiovascular Death or Target Vessel MI	Through 12 months post procedure	Target Vessel Related Death or MI
Percentage of Participants With Composite of All-cause Death or MI	Through 12 months post-procedure	Target vessel or non-target vessel related death or MI
Percentage of Participants With Composite of All-cause Death, MI (Target Vessel or Non-target Vessel), or TVR	Through 12 months post-procedure	Any Death, any MI and any Target Vessel Revascularization
Percentage of Participants With Composite of Probable or Definite Stent Thrombosis	Through 12 months post-procedure	Defined as per the Academic Research Consortium (ARC-2) criteria
Percentage of Participants With Probable Stent Thrombosis	Through 12 months post-procedure	Defined as per the Academic Research Consortium (ARC-2) criteria
Percentage of Participants With Definite Stent Thrombosis	Through 12 months	Defined as per the Academic Research Consortium (ARC-2) criteria

Trial Locations

Locations (36): AZ Middelheim Hospital
🇧🇪
Antwerp, Belgium
Elisabeth Krankenhaus Essen
🇩🇪
Essen, Germany
Kerkhoff Klinik GmbH
🇩🇪
Bad Nauheim, Germany
St. Johannes Hospital
🇩🇪
Dortmund, Germany
UKSH Kiel Klinik
🇩🇪
Kiel, Germany
Universitätsmedizin-Mainz
🇩🇪
Mainz, Germany
Auckland City Hospital
🇳🇿
Auckland, New Zealand
Middlemore Clinical Trials Trust
🇳🇿
Auckland, New Zealand
Segeberger Kliniken GmbH
🇩🇪
Bad Segeberg, Germany
REGIOMED Klinikum Coburg
🇩🇪
Coburg, Germany
Takahashi Hospital
🇯🇵
Tsuchiura City, Ibaraki-Ken, Japan
Waikato Hospital
🇳🇿
Auckland, New Zealand
Dunedin Hospital
🇳🇿
Dunedin, New Zealand
North Shore Hospital
🇳🇿
Takapuna, New Zealand
Kokura Memorial Hospital
🇯🇵
Kitakyushu City, Fukuoka-Ken, Japan
Universitatsklinikum Erlangen
🇩🇪
Erlangen, Germany
Christchurch Hospital
🇳🇿
Christchurch, New Zealand
MVZ CCB Frankfurt
🇩🇪
Frankfurt, Germany
Universitatsklinikun Giessen
🇩🇪
Giessen, Germany
AZ Sint Jan Brugge
🇧🇪
Brugge, Belgium
Ziekenhuis Oost-Limburg
🇧🇪
Genk, Belgium
Tsuchiura Kyodo Hospital
🇯🇵
Tsuchiura City, Ibaraki-Ken, Japan
Universitätsklinikum Jena
🇩🇪
Jena, Germany
Krankenhaus der barmherzigen Bruder
🇩🇪
Trier, Germany
Cardiovascular Reaearch Institute
🇯🇵
Tokyo, Japan
Oumi Hachiman City General Medical Center
🇯🇵
Hachiman, Shiga-Ken, Japan
Universitaire Ziekenhuizen Leuven
🇧🇪
Leuven, Belgium
Sapporo Higashi Tokushukai Hospital
🇯🇵
Sapporo, Hokkaido, Japan
Teikyo University Hospital
🇯🇵
Tokyo, Japan
Shinkoga Hospital
🇯🇵
Kurume City, Fukuoka-Ken, Japan
Kumamoto Rousai Hospital
🇯🇵
Kumamoto, Kumamoto-Ken, Japan
Tenyokai Central Hospital
🇯🇵
Kagoshima City, Kagoshima-Ken, Japan
Shonan Kamakura General Hospital
🇯🇵
Kamakura City,, Kanagawa-Ken, Japan
Kanto Rosai Hospital
🇯🇵
Kawasaki-shi, Kanagawa-Ken, Japan
Yokohama City Eastern Hospital
🇯🇵
Yokohama-shi, Kanagawa-Ken, Japan
Miyazaki Medical Association Hospital
🇯🇵
Miyazaki City, Miyazaki-Ken, Japan